Advances in Monoclonal Antibody Therapeutics Targeting Insulin Resistance in Cancer
Monoclonal antibodies targeting IGF-1R, IL-6, IL-1β, TNF-α, PD-1, PD-L1, and CTLA-4 may counteract insulin resistance in cancer.
Asset / Drug
Drug and asset intelligence for Advances with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Immunotherapy
Synthetic biology techniques are enhancing the efficacy of bacteria-based cancer immunotherapies by improving tumor targeting and immune activation.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.